Oncology Centre of Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava and Martin University Hospital, Kollárova 2, 03659, Martin, Slovakia.
East Slovak Oncology Institute, Inc., Rastislavova 43, 04191, Košice, Slovakia.
Strahlenther Onkol. 2020 Jun;196(6):561-568. doi: 10.1007/s00066-020-01579-y. Epub 2020 Feb 3.
Primary hypothyroidism is one of the late complications that can occur after radiation therapy for malignant tumors in the head and neck region. The aim of this retrospective study was to show the validity of the Lyman-Kutcher-Burman (LKB) normal tissue complication model for thyroid gland based on clinical results.
Thyroid function was evaluated by measuring thyroid-stimulating hormone and free thyroxine serum levels before radiation therapy, 3 months after the beginning of radiation therapy, and afterwards at each follow-up visit. Cumulative incidence was calculated using the Kaplan-Meier method. Dose-volume histogram, total dose, fractionation schedule, total duration of the treatment, and other parameters were used for normal tissue complication probability calculation based on the LKB model. The model was evaluated after fitting with the three sets of parameters for grade 2 hypothyroidism: 1) "Emami," where n = 0.22; m = 0.26, and D = 80 Gy; 2) "mean dose," where n = 1; m = 0.27, and D = 60 Gy; and 3) "Lyman EUD," where n = 0.49; m = 0.24, and D = 60 Gy. A value 3.0 Gy was used for α/β ratio RESULTS: Eighty-three patients treated with volumetric modulated arc therapy for head and neck cancers at the University Hospital Martin, Slovakia, from January 2014 to July 2017, were included in the retrospective study. Median follow-up was 1.2 years. Cumulative incidence of hypothyroidism grade 2 or higher after 12 and 24 months was 9.6 and 22.0%, respectively. Normal tissue complication probability values calculated with mean dose and Lyman EUD parameters showed the best correlation with our clinical findings.
Empirically based modelling of normal tissue complication probability was valid for our cohort of patients. With carefully chosen parameters, the LKB model can be used for predicting the normal tissue complication probability value.
原发性甲状腺功能减退症是头颈部恶性肿瘤放射治疗后可能出现的晚期并发症之一。本回顾性研究的目的是基于临床结果展示基于 Lyman-Kutcher-Burman(LKB)正常组织并发症模型的甲状腺有效性。
在放射治疗前、放射治疗开始后 3 个月以及随后的每次随访中,通过测量促甲状腺激素和游离甲状腺素血清水平来评估甲状腺功能。使用 Kaplan-Meier 方法计算累积发生率。使用剂量-体积直方图、总剂量、分割方案、治疗总持续时间和其他参数,根据 LKB 模型计算正常组织并发症概率。该模型使用 3 组 2 级甲状腺功能减退症的参数进行拟合后进行评估:1)“Emami”,其中 n=0.22;m=0.26,D=80Gy;2)“平均剂量”,其中 n=1;m=0.27,D=60Gy;3)“Lyman EUD”,其中 n=0.49;m=0.24,D=60Gy。α/β 比的取值为 3.0Gy。
2014 年 1 月至 2017 年 7 月,斯洛伐克 Martin 大学医院采用容积调强弧形治疗头颈部癌症的 83 例患者被纳入回顾性研究。中位随访时间为 1.2 年。12 个月和 24 个月后,2 级或更高级别的甲状腺功能减退症累积发生率分别为 9.6%和 22.0%。使用平均剂量和 Lyman EUD 参数计算的正常组织并发症概率值与我们的临床发现具有最佳相关性。
对于我们的患者队列,基于经验的正常组织并发症概率模型是有效的。通过仔细选择参数,可以使用 LKB 模型来预测正常组织并发症概率值。